Ladenburg Thalmann Initiates Coverage on BioTime to Buy

Ladenburg Thalmann Initiates Coverage on BioTime(NYSEMKT:BTX). The shares have been rated Buy. The rating by Ladenburg Thalmann was issued on Sep 23, 2016.

BioTime (BTX) shares turned negative on Tuesdays trading session with the shares closing down -0.14 points or -3.53% at a volume of 3,87,205. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4. The peak price level was also seen at $4 while the days lowest was $3.76. Finally the shares closed at $3.83. The 52-week high of the shares is $4.16625 while the 52-week low is $2.02. According to the latest information available, the market cap of the company is $396 M.

BioTime(BTX) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.27M. Analysts had an estimated revenue of $1.70M. Earnings per share were $-0.11. Analysts had estimated an EPS of $-0.17.

Several Insider Transactions has been reported to the SEC. On Jan 22, 2016, Alfred D Kingsley (director officer 10% owner ) sold 300,000 shares at $2.35 per share price.Also, On Nov 11, 2015, Angus C. Russell (director) purchased 50,000 shares at $3.83 per share price.On Nov 10, 2015, Stephen C Farrell (director) purchased 50,000 shares at $3.83 per share price, according to the Form-4 filing with the securities and exchange commission.

BioTime Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines including tissue banking cellular therapy gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases such as neurological disorders cancer age related macular degeneration orthopedic disorders and age-related cardiovascular disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *